U.S. Markets closed
  • S&P 500

    3,783.28
    -7.65 (-0.20%)
     
  • Dow 30

    30,273.87
    -42.43 (-0.14%)
     
  • Nasdaq

    11,148.64
    -27.76 (-0.25%)
     
  • Russell 2000

    1,762.69
    -13.08 (-0.74%)
     
  • Crude Oil

    88.01
    +0.25 (+0.28%)
     
  • Gold

    1,725.50
    +4.70 (+0.27%)
     
  • Silver

    20.64
    +0.09 (+0.44%)
     
  • EUR/USD

    0.9897
    -0.0089 (-0.8907%)
     
  • 10-Yr Bond

    3.7590
    +0.1420 (+3.93%)
     
  • Vix

    28.55
    -0.52 (-1.79%)
     
  • GBP/USD

    1.1337
    -0.0138 (-1.1995%)
     
  • USD/JPY

    144.4880
    +0.2890 (+0.2004%)
     
  • BTC-USD

    20,146.51
    -147.89 (-0.73%)
     
  • CMC Crypto 200

    456.09
    -2.31 (-0.50%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,120.53
    +128.33 (+0.48%)
     

Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

·1 min read

MENLO PARK, Calif., August 30, 2022--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY.

About Personalis

Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and blog and follow Personalis on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005167/en/

Contacts

Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678

Media Contact:
Jennifer Temple
pr@personalis.com
www.personalis.com
650-752-1300